At a glance
ClinicalIndex Comparison RecordPhase 2Active· 40 enrolled
Drug / intervention
Afatinib Dimaleatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations
In Brief
A Phase 2 clinical trial evaluating Afatinib Dimaleate for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 40 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations. Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Researchers hope to learn if afatinib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartAug 2015
First PostedJun 2020
Primary CompletionJan 2021
TodayJul 2026
Study CompletionMar 2027
First PostedJun 19, 2020
Enrollment StartAug 12, 2015
Primary CompletionJan 22, 2021
Study CompletionMar 3, 2027
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 6.0 years ago
Interventions
Afatinib Dimaleatedrug
Given PO